Overview

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
Phase:
Phase 3
Details
Lead Sponsor:
AGC Biologics S.p.A.
MolMed S.p.A.